Chai Discovery
San Francisco, California, United States · Artificial Intelligence, Biotechnology, Health Care · 36 employees
Chai Discovery is the developer of an AI-based molecular interactions platform designed for molecular structure prediction that performs state-of-the-art across tasks relevant to drug discovery. The company's platform operates models that can predict the structure of biochemical molecules and reprogram how they interact for developing new medications, enabling researchers to get unified prediction
Funding history
- Series C · $400.0M · Jul 2026
- Series B · $130.0M · Dec 2025
Recent signals
- Jul 14, 2026: Raised $400.0M in Series C
- Jun 05, 2026: Chai Discovery Signs License Agreement with Pfizer to Enhance AI in Drug Discovery.
- Jan 09, 2026: Chai Discovery partners with Eli Lilly to enhance biologics discovery using AI technology.
- Dec 15, 2025: Raised $130.0M in Series B
See plans & pricing → Track Chai Discovery’s funding, hiring and signals, with verified contacts, on Fundz.
Fundz watches Chai Discovery across 18 signal types, from funding and M&A to exec moves and hiring.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.